News
Ikarovec set to initiate the next phase of development for their AMD gene therapy with Rentschler Biopharma
Press Release 01 June 2023: Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease Norwich, Stevenage, UK and...
Read MoreIkarovec presents key PoC data on the wAMD and GA programmes at the ARVO and ASGCT conferences in 2023
The Ikarovec team presented key proof-of-concept data identifying lead gene therapy candidates for both the neovascular age-related macular degeneration and geographic atrophy programmes at...
Read MoreIkarovec presents at ARVO 2022 conference
Ikarovec scientific team presented three poster and one oral communication at the Denver Association for Research in Vision and Ophthalmology (ARVO) conference, between 1st...
Read MoreNew Ikarovec CSO Dr Katie Binley brings two decades of gene therapy expertise
Dr Peter Widdowson becomes CTO & company moves to Norwich Research Park Norwich, UK, July 29 2020 – Ikarovec, which is developing novel gene therapies to...
Read MoreIkarovec awarded grant by Innovate UK to develop new wet AMD gene therapy UKI2S Accelerator funding leverages recent investment & advances pipeline
Norwich, June 15 2020 – Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has been awarded £458,740 by Innovate UK, the...
Read MoreIkarovec completes £2.5 million seed funding round.
Ikarovec completes £2.5 million seed funding round. For further details see attachment